These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

616 related items for PubMed ID: 31739554

  • 1. Quadrivalent Influenza Vaccine-Induced Antibody Response and Influencing Determinants in Patients ≥ 55 Years of Age in the 2018/2019 Season.
    Ganczak M, Dubiel P, Drozd-Dąbrowska M, Hallmann-Szelińska E, Szymański K, Brydak LB.
    Int J Environ Res Public Health; 2019 Nov 14; 16(22):. PubMed ID: 31739554
    [Abstract] [Full Text] [Related]

  • 2. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years.
    Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, Esen M, Fernandez Roure JL, Narejos Perez S, Alvarez Sanchez C, Feng Y, Claeys C, Peeters M, Innis BL, Jain V.
    BMC Infect Dis; 2013 Jul 24; 13():343. PubMed ID: 23883186
    [Abstract] [Full Text] [Related]

  • 3. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.
    Tsurudome Y, Kimachi K, Okada Y, Matsuura K, Ooyama Y, Ibaragi K, Kino Y, Ueda K.
    Microbiol Immunol; 2015 Oct 24; 59(10):597-604. PubMed ID: 26272602
    [Abstract] [Full Text] [Related]

  • 4. Immunogenicity and safety of Quadrivalent Influenza HA vaccine in Indonesian children: An open-labeled, bridging, clinical study.
    Dhamayanti M, Tarigan R, Fadlyana E, Prasetyo D, Amalia N, Rusmil VK, Sari RM, Bachtiar NS, Rusmil K, Kartasasmita CB.
    Vaccine; 2020 Jan 29; 38(5):993-1000. PubMed ID: 31862195
    [Abstract] [Full Text] [Related]

  • 5. Randomized, single-blind, active-controlled phase I clinical trial to evaluate the immunogenicity and safety of GC3114 (high-dose, quadrivalent influenza vaccine) in healthy adults.
    Noh JY, Jang YS, Lee SN, Choi MJ, Yoon JG, Yu DH, Song JY, Cheong HJ, Kim WJ.
    Vaccine; 2019 Aug 23; 37(36):5171-5176. PubMed ID: 31377075
    [Abstract] [Full Text] [Related]

  • 6. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years.
    Domachowske JB, Pankow-Culot H, Bautista M, Feng Y, Claeys C, Peeters M, Innis BL, Jain V.
    J Infect Dis; 2013 Jun 15; 207(12):1878-87. PubMed ID: 23470848
    [Abstract] [Full Text] [Related]

  • 7. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial.
    Tinoco JC, Pavia-Ruz N, Cruz-Valdez A, Aranza Doniz C, Chandrasekaran V, Dewé W, Liu A, Innis BL, Jain VK.
    Vaccine; 2014 Mar 14; 32(13):1480-7. PubMed ID: 24486352
    [Abstract] [Full Text] [Related]

  • 8. A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses.
    van de Witte S, Nauta J, Montomoli E, Weckx J.
    Vaccine; 2018 Sep 25; 36(40):6030-6038. PubMed ID: 29709447
    [Abstract] [Full Text] [Related]

  • 9. Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects.
    Choi WS, Noh JY, Song JY, Cheong HJ, Wie SH, Lee JS, Lee J, Kim SW, Jeong HW, Jung SI, Kim YS, Woo HJ, Kim KH, Kim H, Kim WJ.
    Hum Vaccin Immunother; 2017 Jul 03; 13(7):1653-1660. PubMed ID: 28406746
    [Abstract] [Full Text] [Related]

  • 10. Immunogenicity and safety of an egg-based inactivated quadrivalent influenza vaccine (GC3110A) versus two inactivated trivalent influenza vaccines with alternate B strains: A phase Ⅲ randomized clinical trial in adults.
    Song JY, Lee J, Woo HJ, Wie SH, Lee JS, Kim SW, Kim TH, Jung SI, Noh JY, Choi WS, Cheong HJ, Kim WJ.
    Hum Vaccin Immunother; 2019 Jul 03; 15(3):710-716. PubMed ID: 30396317
    [Abstract] [Full Text] [Related]

  • 11. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.
    Pediatrics; 2006 Sep 03; 118(3):e570-8. PubMed ID: 16950948
    [Abstract] [Full Text] [Related]

  • 12. Clinical trial to evaluate the safety and immunogenicity of a trivalent surface antigen seasonal influenza vaccine produced in mammalian cell culture and administered to young and elderly adults with and without A(H1N1) pre-vaccination.
    Loebermann M, Voss U, Meyer S, Bosse D, Fritzsche C, Klammt S, Frimmel S, Riebold D, Reisinger EC.
    PLoS One; 2013 Sep 03; 8(8):e70866. PubMed ID: 23976960
    [Abstract] [Full Text] [Related]

  • 13. Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine in US Children 6-35 Months of Age During 2013-2014: Results From A Phase II Randomized Trial.
    Wang L, Chandrasekaran V, Domachowske JB, Li P, Innis BL, Jain VK.
    J Pediatric Infect Dis Soc; 2016 Jun 03; 5(2):170-9. PubMed ID: 26407273
    [Abstract] [Full Text] [Related]

  • 14. Influenza Vaccine-Induced Antibody Responses Are Not Impaired by Frailty in the Community-Dwelling Elderly With Natural Influenza Exposure.
    Narang V, Lu Y, Tan C, Camous XFN, Nyunt SZ, Carre C, Mok EWH, Wong G, Maurer-Stroh S, Abel B, Burdin N, Poidinger M, Tambyah PA, Bosco N, Visan L, Ng TP, Larbi A.
    Front Immunol; 2018 Jun 03; 9():2465. PubMed ID: 30405641
    [Abstract] [Full Text] [Related]

  • 15. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
    Vesikari T, Kirstein J, Devota Go G, Leav B, Ruzycky ME, Isakov L, de Bruijn M, Oberye J, Heijnen E.
    Lancet Respir Med; 2018 May 03; 6(5):345-356. PubMed ID: 29631857
    [Abstract] [Full Text] [Related]

  • 16. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM.
    Pediatrics; 2006 Sep 03; 118(3):e579-85. PubMed ID: 16950949
    [Abstract] [Full Text] [Related]

  • 17. A 2013/2014 northern hemisphere season surface antigen inactivated trivalent influenza vaccine--Assessing the immunogenicity and safety in an open label, uncontrolled study.
    Roggelin L, Vinnemeier CD, Meyer S, Witte K, Marx L, Theeß W, Burchard GD, Rolling T, Cramer JP.
    Hum Vaccin Immunother; 2015 Sep 03; 11(10):2370-5. PubMed ID: 26114800
    [Abstract] [Full Text] [Related]

  • 18. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age.
    Rodriguez Weber MA, Claeys C, Aranza Doniz C, Feng Y, Innis BL, Jain VK, Peeters M.
    Pediatr Infect Dis J; 2014 Dec 03; 33(12):1262-9. PubMed ID: 25386965
    [Abstract] [Full Text] [Related]

  • 19. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: a randomized, double-blind, controlled phase III clinical trial in children aged 6-35 months in China.
    Hu Y, Shao M, Hu Y, Liang Q, Jia N, Chu K, Xu L, Li J, Li C, Zhu F.
    Hum Vaccin Immunother; 2020 Jul 02; 16(7):1691-1698. PubMed ID: 32347785
    [Abstract] [Full Text] [Related]

  • 20. Assessment of Immunogenicity of Adjuvanted Quadrivalent Inactivated Influenza Vaccine in Healthy People and Patients With Common Variable Immune Deficiency.
    Kostinova AM, Akhmatova NK, Latysheva EA, Dagil YA, Klimova SV, Vlasenko AE, Khromova EA, Latysheva TV, Kostinov MP.
    Front Immunol; 2020 Jul 02; 11():1876. PubMed ID: 32973775
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.